BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BNTX BioNTech SE

交易中 07-22 14:54:12 EDT

85.47

+0.01

+0.01%

最高86.80	最低84.42	成交量23.90万
今开86.72	昨收85.46	日振幅2.78%
总市值206.24亿	流通市值77.37亿	总股本2.41亿
成交额2,032万	换手率0.26%	流通股本9,053万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BNTX","market":"US","secType":"STK","nameCN":"BioNTech SE","latestPrice":85.465,"timestamp":1721674449216,"preClose":85.46,"halted":0,"volume":239014,"delay":0,"floatShares":90526196,"shares":241318632,"eps":0.501233,"marketStatus":"交易中","marketStatusCode":2,"change":0.005,"latestTime":"07-22 14:54:12 EDT","open":86.72,"high":86.8,"low":84.42,"amount":20318176.20634,"amplitude":0.027849,"askPrice":85.5,"askSize":331,"bidPrice":85.38,"bidSize":57,"shortable":3,"etf":0,"ttmEps":0.501233,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721678400000},"adr":0,"listingDate":1570680000000,"adjPreClose":85.46,"adrRate":1,"preHourTrading":{"tag":"盘前","latestPrice":86.75,"preClose":85.46,"latestTime":"09:26 EDT","volume":3369,"amount":290049.81006,"timestamp":1721654816920},"postHourTrading":{"tag":"盘后","latestPrice":86.03,"preClose":85.46,"latestTime":"19:29 EDT","volume":83226,"amount":7114798.472,"timestamp":1721431781409},"volumeRatio":0.595051,"impliedVol":0.3995,"impliedVolPercentile":0.7171},"requestUrl":"/m/hq/s/BNTX/wiki","defaultTab":"wiki","newsList":[{"id":"2450367535","title":"抗疫概念股普遍扬升 诺瓦瓦克斯医药(NVAX)涨逾4% 美国疾控中心建议年龄满6个月及以上人群接种疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2450367535","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450367535?lang=zh_cn&edition=full","pubTime":"2024-07-12 21:57","pubTimestamp":1720792643,"startTime":"0","endTime":"0","summary":"金吾财讯 | 抗疫概念股普遍扬升，诺瓦瓦克斯医药(NVAX)涨4.32%，Moderna(MRNA)涨3.41%，BioNTech(BNTX)涨2.20%，阿斯利康(AZN)涨1.92%，美疾病预防控制中心关于COVID-19的最新数据显示，截至6月底，44个州的感染人数正在增加或可能增加。美国疾病控制与预防中心建议年龄六个月及以上的人接种更新的COVID-19疫苗。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/MGY3NWNiZjgxNDI5NTMwNTcxNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGY3NWNiZjgxNDI5NTMwNTcxNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"277731","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","NVAX","LU0109394709.USD","BK4501","MRNA","BK4551","LU0320765992.SGD","BK4007","BNTX","LU1829250122.USD","LU0889565916.HKD","BK4535","BK4548","BK4585","BK4532","159646","BK4588","AZN","LU2236285917.USD","BK4568","BK4534","BK4139","BK4547"],"gpt_icon":0},{"id":"2450833398","title":"Biontech Se盘中异动 大幅拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450833398","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450833398?lang=zh_cn&edition=full","pubTime":"2024-07-12 00:09","pubTimestamp":1720714150,"startTime":"0","endTime":"0","summary":"北京时间2024年07月12日00时09分，Biontech Se股票出现波动，股价急速上涨5.02%。截至发稿，该股报85.38美元/股，成交量36.6615万股，换手率0.15%，振幅4.29%。Biontech Se股票所在的生物技术行业中，整体涨幅为0.38%。Biontech Se公司简介：BioNTech 是一家总部位于德国的生物技术公司，专注于开发癌症疗法，包括个体化免疫疗法，以及包括新冠病毒在内的传染病疫苗。BioNTech 与多家大型制药公司合作，包括罗氏、礼来、辉瑞、赛诺菲和 Genmab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712000910941f653f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712000910941f653f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4535","BK4585","BK4551","BK4548","BK4568","BNTX"],"gpt_icon":0},{"id":"2450033439","title":"更新版 1-Emergent 与 J&J 就 COVID 疫苗供应交易纠纷达成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2450033439","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450033439?lang=zh_cn&edition=full","pubTime":"2024-07-09 05:51","pubTimestamp":1720475486,"startTime":"0","endTime":"0","summary":"     路透7月8日 - Emergent BioSolutions   周一称，强生公司  已同意支付5,000万美元，以解决与后者COVID-19疫苗生产协议终止有关的索赔。该公司股价在延时交易中上涨了约2%。2022年，J&J通知Emergent公司决定终止交易，理由是  合同制造商违反了  ，包括未能提供COVID-19疫苗药物物质。Emergent称，J&J违反了协议，未能购买该公司生产的最低数量的COVID-19疫苗。由于存在罕见的凝血综合症风险 ， 美国卫生监管机构 限制   在 2022 年使用 J&J 疫苗 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0889566641.SGD","LU1221951129.SGD","LU1074936037.SGD","LU0114720955.EUR","LU1196500208.SGD","BK4551","BK4585","IE00B19Z3581.USD","BNTX","LU1244550221.USD","LU0466842654.USD","BK4007","BK4548","LU1506573853.SGD","BK4559","JNJ","LU1280957306.USD","LU1732799900.SGD","LU1066051498.USD","SG9999002232.USD","BK4592","BK4534","LU0795875169.SGD","LU1430594728.SGD","LU1066053197.SGD","LU1059921491.USD","LU0640476718.USD","BK4533","LU0122379950.USD","BK4139","LU0795875086.SGD","LU0320765646.SGD","LU1032955483.USD","LU2602419157.SGD","SG9999002224.SGD","BK4535","LU0882574055.USD","LU1221951046.USD","LU1244550494.USD","LU1935042991.SGD","BK4550","EBS","LU1032466523.USD","IE00B19Z3B42.SGD","BK4532","BK4568","BK4583","LU2133065610.SGD","LU1162221912.USD"],"gpt_icon":0},{"id":"2450384380","title":"J&J 向 Emergent 支付 5000 万美元，以解决 COVID 疫苗生产交易问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2450384380","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450384380?lang=zh_cn&edition=full","pubTime":"2024-07-09 05:21","pubTimestamp":1720473710,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透7月8日 - Emergent BioSolutions   周一称，强生公司  已同意支付5,000万美元，以解决与后者终止COVID-19疫苗生产协议有关的索赔。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","EBS","BK4585","JNJ","BK4535","BK4139","BK4568","BK4548","BK4583","BK4551","BNTX"],"gpt_icon":0},{"id":"2446593326","title":"美国疾病预防控制中心顾问建议 6 个月及以上儿童接种更新的 COVID 疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2446593326","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446593326?lang=zh_cn&edition=full","pubTime":"2024-06-28 04:54","pubTimestamp":1719521698,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透6月27日 - 美国疾病控制和预防中心的一个外部专家小组建议在 2024-25 年的免疫接种活动中，在六个月及以上的人群中使用经美国食品药品管理局批准的更新版 COVID-19 疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4535","BK4533","BK4547","MRNA","BK4534","NVAX","BK4568","BK4588","BNTX","BK4585","BK4532","BK4551","BK4139","BK4501"],"gpt_icon":0},{"id":"2446360121","title":"更新版 1-罗维收到制造业务非约束性报价","url":"https://stock-news.laohu8.com/highlight/detail?id=2446360121","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446360121?lang=zh_cn&edition=full","pubTime":"2024-06-26 20:42","pubTimestamp":1719405736,"startTime":"0","endTime":"0","summary":"     路透马德里6月26日 - 西班牙制药公司罗维  周三表示，已收到对其第三方生产业务的非约束性报价，但未透露竞标者的名称。据《Expansion》周三早些时候报道，投资基金Antin   、Cinven、CVC   、KKR   和Permira已经提交了竞标书。据该报报道，这五家公司于 6 月 13 日提交了非约束性出价，目前正处于约束性出价的尽职调查过程中。Cinven和KKR的发言人拒绝置评，而Antin、CVC和Permira没有立即回应置评请求。Expansion公司表示，该业务估计价值约35亿欧元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX","BK4135","KKR","BK4139","LU1935042991.SGD","LU0130102774.USD","BK4535","BK4568","LU1935043536.SGD","LU0648001328.SGD","LU0106831901.USD","LU0980610538.SGD","BK4548","LU1935043023.USD","BK4585","BK4551","LU1201861249.SGD","BK4588","LU1668664300.SGD"],"gpt_icon":0},{"id":"2446495188","title":"德国上诉法院驳回对接种 COVID 疫苗的医生的索赔要求","url":"https://stock-news.laohu8.com/highlight/detail?id=2446495188","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446495188?lang=zh_cn&edition=full","pubTime":"2024-06-25 21:34","pubTimestamp":1719322468,"startTime":"0","endTime":"0","summary":"    路透法兰克福6月25日 - 德国斯图加特市的一家上诉法院周二驳回了对一名医生提出的损害赔偿要求，该医生被指控未就其接种的 COVID-19 疫苗可能造成的伤害发出警告。斯图加特市高等地方法院在一份声明中说，这一判决是德国上诉法院作出的首个此类裁决。德国法院受理了一系列针对 COVID 疫苗生产商的损害赔偿要求，这些要求以所谓的副作用为由提出，但迄今为止尚未成功。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4551","BK4535","BK4548","BK4568","BK4585","BK4588","PFE","BNTX"],"gpt_icon":0},{"id":"2444512329","title":"堪萨斯州指控辉瑞在COVID-19疫苗问题上误导公众","url":"https://stock-news.laohu8.com/highlight/detail?id=2444512329","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444512329?lang=zh_cn&edition=full","pubTime":"2024-06-18 10:13","pubTimestamp":1718676811,"startTime":"0","endTime":"0","summary":"美国堪萨斯州周一起诉辉瑞，指控该公司在COVID-19疫苗问题上误导公众，隐瞒风险，同时虚假宣称其有效性。在向托马斯县地方法院提起的诉讼中，该州称辉瑞被指控的虚假陈述违反了《堪萨斯州消费者保护法》，该州正在寻求未指定数额的赔偿金。诉讼称，从2021年初疫苗推出后不久，辉瑞公司隐瞒了该疫苗与妊娠并发症（包括流产）以及心脏内部和周围炎症（即心肌炎和心包炎）有关的证据。辉瑞公司在一份声明中称，公司就COVID-19疫苗所做的陈述是准确和有科学依据的。\n\n\r\n            责任编辑：栎树","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/06/18101341066199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0321505868.SGD","BK4548","IE00BLSP4239.USD","BK4534","LU0058720904.USD","SG9999001176.USD","BK4550","BK4585","SG9999013999.USD","SGXZ57979304.SGD","BK4588","BK4592","LU0868494617.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","PFE","SG9999002232.USD","LU0234572021.USD","SG9999001176.SGD","LU0170899867.USD","SG9999002224.SGD","IE0002270589.USD","LU1023059063.AUD","BK4581","BK4139","159646","LU0122379950.USD","LU1057294990.SGD","LU0321505439.SGD","BNTX","IE00B19Z3581.USD","IE00BLSP4452.SGD","BK4533","SG9999003800.SGD","LU0456855351.SGD","SG9999011175.SGD","LU1066051498.USD","IE00BBT3K403.USD","BK4568","BK4551","BK4007","LU0289739699.SGD","BK4535"],"gpt_icon":0},{"id":"2444926891","title":"Biontech Se盘中异动 快速跳水5.03%报87.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444926891","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444926891?lang=zh_cn&edition=full","pubTime":"2024-06-18 00:45","pubTimestamp":1718642756,"startTime":"0","endTime":"0","summary":"北京时间2024年06月18日00时45分，Biontech Se股票出现波动，股价快速跳水5.03%。截至发稿，该股报87.45美元/股，成交量51.8788万股，换手率0.22%，振幅4.07%。Biontech Se股票所在的生物技术行业中，整体跌幅为0.39%。Biontech Se公司简介：BioNTech 是一家总部位于德国的生物技术公司，专注于开发癌症疗法，包括个体化免疫疗法，以及包括新冠病毒在内的传染病疫苗。BioNTech 与多家大型制药公司合作，包括罗氏、礼来、辉瑞、赛诺菲和 Genmab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240618004556aef54c47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240618004556aef54c47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4535","BK4139","BK4568","BK4548","BK4551","BNTX"],"gpt_icon":0},{"id":"2443526106","title":"美国政府将为口服和鼻腔接种 COVID 疫苗的研究提供高达 5 亿美元的资助","url":"https://stock-news.laohu8.com/highlight/detail?id=2443526106","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443526106?lang=zh_cn&edition=full","pubTime":"2024-06-14 06:28","pubTimestamp":1718317707,"startTime":"0","endTime":"0","summary":"    路透6月13日 - 美国卫生与公众服务部 周四表示，它将提供高达 5 亿美元的资金用于中期试验，评估以鼻腔喷雾或药片形式接种疫苗以预防症状性 COVID-19 的情况。生物医学高级研究与发展管理局隶属于美国卫生与公共服务部，负责帮助企业开发医疗用品以应对公共卫生威胁。该项目将向Vaxart   提供高达4.53亿美元的资金，用于评估其口服COVID疫苗的研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4535","BK4585","BK4139","BK4009","BK4588","BNTX","HHS","BK4548","BK4568","VXRT"],"gpt_icon":0},{"id":"2443509444","title":"莫德纳的下一代COVID疫苗显示不劣于现有疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2443509444","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443509444?lang=zh_cn&edition=full","pubTime":"2024-06-13 19:09","pubTimestamp":1718276959,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透6月13日 - 莫德纳   公司周四称，其下一代COVID-19候选疫苗在一项后期研究中达到了主要目标，与该公司的商业疫苗相比，疫苗疗效毫不逊色。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4501","MRNA","BNTX","BK4551","BK4533","BK4139","BK4534","BK4535","BK4588","BK4548","BK4585","BK4532"],"gpt_icon":0},{"id":"2442549195","title":"Biontech Se涨2.29% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2442549195","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442549195?lang=zh_cn&edition=full","pubTime":"2024-06-12 21:31","pubTimestamp":1718199107,"startTime":"0","endTime":"0","summary":"北京时间2024年06月12日21时31分，Biontech Se股票出现异动，股价快速拉升2.29%。Biontech Se股票所在的生物技术行业中，整体涨幅为0.34%。Biontech Se公司简介：BioNTech 是一家总部位于德国的生物技术公司，专注于开发癌症疗法，包括个体化免疫疗法，以及包括新冠病毒在内的传染病疫苗。BioNTech 与多家大型制药公司合作，包括罗氏、礼来、辉瑞、赛诺菲和 Genmab。消息层面，截至21时31分，《H.C. Wainwright维持BioNTech买入评级，维持目标价113美元》资讯为影响Biontech Se的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406122131479f352aaa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406122131479f352aaa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","BK4568","BK4139","BNTX","BK4585","BK4548","BK4588","BK4551"],"gpt_icon":0},{"id":"2442845231","title":"莫德纳新冠与流感综合疫苗试验有效，可能领先辉瑞及诺瓦瓦克斯医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2442845231","media":"鉅亨网","labels":["movement"],"top":-1,"share":"https://www.laohu8.com/m/news/2442845231?lang=zh_cn&edition=full","pubTime":"2024-06-10 18:56","pubTimestamp":1718016982,"startTime":"0","endTime":"0","summary":"其针对新冠病毒和流感的组合疫苗比针对这两种病毒的现有单独疫苗更有效。","market":"us","thumbnail":"https://cimg.cnyes.cool/prod/news/5593882/xs/0c0d9fcd6fa52bb291485a9021d3c97f.jpg","type":0,"news_type":0,"thumbnails":["https://cimg.cnyes.cool/prod/news/5593882/xs/0c0d9fcd6fa52bb291485a9021d3c97f.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://news.cnyes.com/news/id/5593882?exp=a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"cnyes_highlight","symbols":["NVAX","PFE","MRNA","BNTX"],"gpt_icon":0},{"id":"2441067204","title":"更新版 1-美国 FDA 称，COVID 注射应针对 2024-25 年的 JN.1 变异株","url":"https://stock-news.laohu8.com/highlight/detail?id=2441067204","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441067204?lang=zh_cn&edition=full","pubTime":"2024-06-07 23:10","pubTimestamp":1717773039,"startTime":"0","endTime":"0","summary":"     路透6月7日 - 美国食品和药物管理局周五建议 COVID-19 疫苗生产商，2024 年秋季的新疫苗应针对今年早些时候占主导地位的 JN.1 变种。美国食品和药物管理局的这一建议与欧洲和世界卫生组织的建议一致，在此之前，美国该机构的顾问们以压倒性多数支持以较老的 JN.1 株为目标，而不是现在占主导地位的 KP.2 株。另外，另一家疫苗生产商莫德纳   周五表示，它已向美国食品与药物管理局 提交了 针对JN.1菌株的 COVID-19疫苗申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234572021.USD","LU0170899867.USD","BK4501","SG9999001176.USD","BK4585","SG9999001176.SGD","SG9999002224.SGD","BK4548","SG9999011175.SGD","IE00B19Z3581.USD","BNTX","SG9999003800.SGD","BK4533","IE00BLSP4239.USD","LU0456855351.SGD","BK4535","SG9999002232.USD","IE00BLSP4452.SGD","SG9999013999.USD","LU1066051498.USD","NVAX","BK4588","BK4534","LU0058720904.USD","LU0289739699.SGD","SGXZ57979304.SGD","IE00BBT3K403.USD","LU0868494617.USD","LU1057294990.SGD","BK4551","IE00B19Z3B42.SGD","LU1023059063.AUD","LU1066053197.SGD","MRNA","BK4532","BK4550","IE0002270589.USD","BK4568","BK4139","BK4581","LU0122379950.USD","BK4007","PFE","BK4592"],"gpt_icon":0},{"id":"2441716915","title":"BUZZ-美国 FDA 顾问建议在 2024-25 年期间注射 COVID-19 疫苗后，Novavax 公司股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2441716915","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441716915?lang=zh_cn&edition=full","pubTime":"2024-06-06 20:23","pubTimestamp":1717676617,"startTime":"0","endTime":"0","summary":"    6月6日 - ** Novavax  股价盘前上涨16%至24.31美元 ** 周三晚些时候，美国卫生监管机构的顾问建议 ，2024-25年的COVID-19疫苗应针对今年占主导地位的JN.1变种。** NVAX 曾在 5 月份表示 ，只有 监管机构接受其 针对较早 JN.1 变异株的疫苗，它才能在今年秋季在美国提供 COVID-19 疫苗。** NVAX公司表示，预计该疫苗将于9月投入商业生产** 莫德纳   公司开发了基于mRNA的COVID-19疫苗，该公司股价盘前上涨2.4%，报158.5美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4547","BK4548","BK4501","BK4534","MRNA","BUZZ","NVAX","BK4532","BK4585","BNTX","BK4588","BK4568","BK4551","BK4533","BK4535"],"gpt_icon":0},{"id":"2441207644","title":"美国 FDA 顾问称，2024-25 年的 COVID 注射应以 JN.1 或更新的变体为目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2441207644","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441207644?lang=zh_cn&edition=full","pubTime":"2024-06-06 02:56","pubTimestamp":1717613815,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透6月5日 - 美国食品和药物管理局的顾问们周三一致投票赞成 ，建议2024-25年的COVID-19疫苗应针对今年占主导地位的JN.1变异株系中的一种毒株。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4551","BK4535","BK4548","BK4568","BK4585","BK4588","BNTX"],"gpt_icon":0},{"id":"2441727812","title":"Biontech Se涨0.55% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2441727812","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441727812?lang=zh_cn&edition=full","pubTime":"2024-06-05 22:33","pubTimestamp":1717598025,"startTime":"0","endTime":"0","summary":"北京时间2024年06月05日22时33分，Biontech Se股票出现波动，股价快速拉升0.55%。截至发稿，该股报100.03美元/股，成交量15.5881万股，换手率0.06%，振幅1.41%。Biontech Se股票所在的生物技术行业中，整体涨幅为0.85%。Biontech Se公司简介：BioNTech 是一家总部位于德国的生物技术公司，专注于开发癌症疗法，包括个体化免疫疗法，以及包括新冠病毒在内的传染病疫苗。BioNTech 与多家大型制药公司合作，包括罗氏、礼来、辉瑞、赛诺菲和 Genmab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605223346aef39100&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605223346aef39100&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4585","BK4551","BK4139","BK4535","BK4548","BNTX","BK4588"],"gpt_icon":0},{"id":"2440494635","title":"BUZZ-美国 FDA 将考虑更新 COVID 疫苗的 JN.1 变体，Novavax 受益匪浅","url":"https://stock-news.laohu8.com/highlight/detail?id=2440494635","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440494635?lang=zh_cn&edition=full","pubTime":"2024-06-03 23:03","pubTimestamp":1717427004,"startTime":"0","endTime":"0","summary":"    6月3日 - ** 疫苗制造商Novavax    的股票在早盘交易中上涨约 13%，至 17.02 美元 ** 美国食品和药物管理局 评审人员称，COVID-19 疫苗生产商应考虑将目前占主导地位的 JN.1 变体和 JN.1 衍生亚变体中的一种作为 2024-25 疫苗生产的目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4534","BK4547","BK4551","SG9999002224.SGD","BNTX","BK4568","LU0122379950.USD","LU0234572021.USD","MRNA","BK4548","IE00BLSP4452.SGD","IE00BBT3K403.USD","BK4532","BK4592","BK4501","SG9999001176.SGD","SG9999003800.SGD","SG9999002232.USD","LU1066051498.USD","LU0289739699.SGD","BUZZ","BK4581","BK4588","LU0868494617.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","BK4533","SG9999001176.USD","LU1023059063.AUD","PFE","IE0002270589.USD","SG9999013999.USD","BK4585","SGXZ57979304.SGD","LU0456855351.SGD","LU1057294990.SGD","BK4550","IE00B19Z3581.USD","SG9999011175.SGD","BK4007","BK4535","LU0058720904.USD","LU0170899867.USD","NVAX","LU1066053197.SGD"],"gpt_icon":0},{"id":"2440493735","title":"Biontech Se跌0.79% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2440493735","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440493735?lang=zh_cn&edition=full","pubTime":"2024-06-03 21:31","pubTimestamp":1717421486,"startTime":"0","endTime":"0","summary":"北京时间2024年06月03日21时31分，Biontech Se股票出现异动，股价快速下跌0.79%。截至发稿，该股报99.81美元/股，成交量2.6823万股，换手率0.01%，振幅0.37%。Biontech Se股票所在的生物技术行业中，整体跌幅为0.35%。Biontech Se公司简介：BioNTech 是一家总部位于德国的生物技术公司，专注于开发癌症疗法，包括个体化免疫疗法，以及包括新冠病毒在内的传染病疫苗。BioNTech 与多家大型制药公司合作，包括罗氏、礼来、辉瑞、赛诺菲和 Genmab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240603213126958a0421&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240603213126958a0421&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BNTX","BK4551","BK4568","BK4535","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2438275371","title":"宜联生物与BioNTech(BNTX.US)达成TMALIN®ADC技术平台授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2438275371","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438275371?lang=zh_cn&edition=full","pubTime":"2024-05-28 21:12","pubTimestamp":1716901948,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月27日，宜联生物宣布与BioNTech达成新的战略合作。基于本次合作，BioNTech将获得利用宜联生物TMALINADC技术平台开发针对限定的某几个前沿创新靶点的ADC产品的独家选择权及相应全球独家许可。本次平台合作许可协议的签署，标志着宜联生物与BioNTech之间战略合作伙伴关系进一步巩固，为双方在ADC领域的研发合作奠定了新基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528211508956f04fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528211508956f04fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BNTX","BK4080","BK4548","BK4551","BK4139","BK4231","ADC","BK4568","BK4585","BK4588","BK4535"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biontech.de","stockEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0094},{"period":"3month","weight":-0.0156},{"period":"6month","weight":-0.1299},{"period":"1year","weight":-0.2066},{"period":"ytd","weight":-0.1903}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BioNTech SE成立于2008年6月2日。该公司结合了数十年的免疫学，尖端治疗平台以及各种患者分析和生物信息学工具的开创性研究，开发针对癌症和其他疾病的个体化免疫疗法。该公司利用强大的新治疗机制，利用各种生物学靶点，利用每位患者免疫系统的力量，解决每位患者潜在疾病的独特分子特征。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.036134},{"month":2,"riseRate":0.2,"avgChangeRate":-0.029347},{"month":3,"riseRate":0.8,"avgChangeRate":0.158218},{"month":4,"riseRate":0.2,"avgChangeRate":0.046183},{"month":5,"riseRate":0.8,"avgChangeRate":0.071246},{"month":6,"riseRate":0.6,"avgChangeRate":0.036711},{"month":7,"riseRate":1,"avgChangeRate":0.17535},{"month":8,"riseRate":0.5,"avgChangeRate":-0.066227},{"month":9,"riseRate":0.25,"avgChangeRate":-0.052386},{"month":10,"riseRate":0.75,"avgChangeRate":0.033872},{"month":11,"riseRate":1,"avgChangeRate":0.26222},{"month":12,"riseRate":0.4,"avgChangeRate":-0.023804}],"exchange":"NASDAQ","name":"BioNTech SE","nameEN":"BioNTech SE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioNTech SE,BNTX,BioNTech SE股票,BioNTech SE股票老虎,BioNTech SE股票老虎国际,BioNTech SE行情,BioNTech SE股票行情,BioNTech SE股价,BioNTech SE股市,BioNTech SE股票价格,BioNTech SE股票交易,BioNTech SE股票购买,BioNTech SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}